Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

China Continuation: A Single-Arm, Open-Label Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

NCT03748953 is registered in ClinicalTrials.gov with Millennium Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03748953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03748953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
China Continuation: A Single-Arm, Open-Label Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
Lead sponsor
Millennium Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
January 24, 2019
Completion date
December 6, 2023
Enrollment
37 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma